Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Fondazione Michelangelo
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03595592CT.gov Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT03206203CT.gov Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT02883062CT.gov Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT02530489CT.gov Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Invasive Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atezolizumab (this asset) | Fondazione Michelangelo | P3 | B · 62 |
| Tamoxifen | University of California, San Francisco | P4 | BBB |
| Letrozole | Emory University | P4 | BBB |
| Anastrozole | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Exemestane | University of California, San Francisco | P4 | BBB |
| Carboplatin | Baylor Breast Care Center | P3 | BB |
| Trastuzumab | Massachusetts General Hospital | P3 | BB |
| Fulvestrant | Massachusetts General Hospital | P2 | BB |
| Pertuzumab | Baylor Breast Care Center | P3 | BB |
+42 more in the Invasive Breast Carcinoma cohort
Other indications for Atezolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metastatic Neoplasm | — | P2/3 | BB · 71 |
| Her2-Receptor Negative Breast Cancer | — | P2 | BB · 69 |
| Bladder Transitional Cell Carcinoma | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atezolizumab in Invasive Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atezolizumab-invasive-breast-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →